lenalidomide stada 10 mg cietās kapsulas
stada arzneimittel ag, germany - lenalidomīds - kapsula, cietā - 10 mg
lenalidomide stada 25 mg cietās kapsulas
stada arzneimittel ag, germany - lenalidomīds - kapsula, cietā - 25 mg
lenalidomide zentiva 10 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 10 mg
lenalidomide zentiva 15 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 15 mg
lenalidomide zentiva 25 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 25 mg
lenalidomide zentiva 5 mg cietās kapsulas
zentiva, k.s., czech republic - lenalidomīds - kapsula, cietā - 5 mg
lenalidomide stada 5 mg cietās kapsulas
stada arzneimittel ag, germany - lenalidomīds - kapsula, cietā - 5 mg
lenalidomide stada 15 mg cietās kapsulas
stada arzneimittel ag, germany - lenalidomīds - kapsula, cietā - 15 mg
lenalidomide accord
accord healthcare s.l.u. - lenalidomide - multiple mieloma - imūnsupresanti - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide vienojoties kopā ar deksametazona ir indicēts, lai ārstētu multiplā mieloma pieaugušo pacientiem, kuri ir saņēmuši vismaz vienu pirms terapijas. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
lenalidomide mylan
mylan ireland limited - lenalidomide - multiple mieloma - imūnsupresanti - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).